A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis

NCT00089791 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 7808

Last updated 2022-11-08

Study results available
· View outcomes & findings →

Summary

This study will evaluate the effectiveness and safety of denosumab in treating women with Postmenopausal Osteoporosis.

Conditions

Interventions

DRUG

placebo

Placebo administered by subcutaneous injection

DRUG

Denosumab

Denosumab 60 mg administered by subcutaneous injection

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-01
Primary Completion
2008-06-17
Completion
2008-06-17

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00089791 on ClinicalTrials.gov